Sucampo Pharmaceuticals, Inc. has amended its existing collaboration and license agreement with Takeda Pharmaceutical Co. covering the U.S. and Canada for AMITIZA (lubiprostone). The current term has been extended, along with minimum commercial investment and various governance changes allowing Takeda additional flexibility in commercializing AMITIZA.
 
During the extended term beginning January 1, 2021, Takeda will split with Sucampo the profits of branded AMITIZA for any dosage strength and form for the existing indications in the U.S. and Canada. On April 1, 2015, Takeda will no longer reimburse Sucampo for the product details made by Sucampo sales representatives.
 
“Today’s announcement of the extended collaboration with Takeda is yet another step toward achieving our objective of securing Sucampo’s foundation and expanding the AMITIZA business. This extended collaboration also allows Sucampo to share in the long-term value of AMITIZA,” said Peter Greenleaf, chief executive officer of Sucampo. “Takeda and Sucampo are aligned in our objectives for the brand, and I believe this newly extended collaboration and license agreement positions the companies more strongly than ever to help grow the AMITIZA business.”